Role of co-receptor modified cells in HIV infection
Role of co-receptor modified cells in HIV infection
批准号:
8469110
负责人:
CARL H. JUNE
金额:
$128.7万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2017-07-31
关键词:
AIDS/HIV problemAdenovirus VectorAdenovirusesAllelesAllogenicAntiviral AgentsAutoimmune DiseasesAutologousBerlinBindingBloodCCRCCR5 geneCD4 Positive T LymphocytesCancer PatientCell TherapyCellsCleaved cellClinical TrialsCyclophosphamideDataDiseaseDoseEngineeringEngraftmentFutureGenerationsGenesGlobulinsGoalsHIVHIV InfectionsHIV-1Highly Active Antiretroviral TherapyHumanImmunotherapyInfusion proceduresInterruptionLymphopeniaMessenger RNAOutcomePatientsPhasePlayProceduresProteinsProtocols documentationRNAResistanceRoleSafetyStructureT-LymphocyteTestingTherapeutic immunosuppressionTissuesZinc Fingersbasechemotherapyconditioningcostdesignexperiencegene therapyhuman dataimprovedinsightmRNA Expressionnovel strategiesnucleasephase 1 studyreceptorresearch clinical testingresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The central hypothesis of this Project 1 is that CCR5-deficient, C04-)- T-cells played a major role in
contributing to the successful outcome of the Berlin patient. Our approach is tiased on our expertise with
cell'based therapies for HIV infection as well as the first in-human data from Infusions of autologous CD4
cells rendered CCRS-deficient by zinc finger nucleases (ZFNs), whk:h bind to, cleave and Inactivate the ccrS
gene. Phase-I data from this trial demonstrated an excellent safety profile as well as efficient, long-temn
engraftment and expansion of the CCRS-modified cells. Furthermore, while not a direct goal of this trial,
intriguing antiviral effects have been observed in 6 subjects at Penn who completed a 12 week treatment
interruption, in this project we will detennine if patient conditioning with a single dose of cyclophosphamide
that is used routinely in autoimmune disorders and to promote immunotherapy can enhance engraftment of
autologous T-cells treated with RS-spedfic ZFNs, and as a result, control HIV In the absence of H/\/^T.
Three specific aims are proposed: (1) Complete the pre-clinical testing necessary to support the
manufacturing of mRNA ZFN modified CD4 T cells; (2) Conduct a proof of concept clinical trial to detennine
the safety of R5 deficient CD4 cells infused in the setting of transient lymphopenia, induced with a single
dose of cyclophosphamide and (3) Evaluate the host and virotogical response to R5-modified T ceil
infusions. We hypothesize that the level of engraftment will increase in the cyclophosphamide-treated
patients, and related to this, ttiat antiviral effects will be uncovered during a structured treatment interruption.
Curing or controlling HIV in the absence of HAART has been an elusive goal, but one that may finally be
realized. The results of our project, conducted with an experienced team in place at Sangamo and Penn will
provide critical information for future protocols to further dtesect the factors that led to cure of the Beriin
patient and provide basic insights into underiying mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of T Cells
-
批准号:10578324
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Engineering the next generation of T cells
-
批准号:10064451
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2019
-
负责人:CARL H. JUNE
-
依托单位:
Directing the metabolic fate of CAR T cells
-
批准号:10364746
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2018
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
-
批准号:10713199
-
项目类别:
-
资助金额:$278.23万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:10245064
-
项目类别:
-
资助金额:$31.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:10245066
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells
-
批准号:9982244
-
项目类别:
-
资助金额:$24.16万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9280418
-
项目类别:
-
资助金额:$289.74万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:9982239
-
项目类别:
-
资助金额:$170.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Biostatistics Core
-
批准号:9982247
-
项目类别:
-
资助金额:$11.2万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
-
批准号:10245062
-
项目类别:
-
资助金额:$219.44万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
Core A: Administrative and Clinical Translational Core
-
批准号:10713203
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2017
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8601689
-
项目类别:
-
资助金额:$48.93万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8889623
-
项目类别:
-
资助金额:$156.67万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8989883
-
项目类别:
-
资助金额:$23.77万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
Role of co-receptor modified cells in HIV infection
-
批准号:8519303
-
项目类别:
-
资助金额:$131.48万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8243893
-
项目类别:
-
资助金额:$51.14万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
CD19 Directed CAR Therapy
-
批准号:8442843
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2012
-
负责人:CARL H. JUNE
-
依托单位:
FACSAria II Cell Sorter for Non-Biohazardous Cells
-
批准号:7793915
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2010
-
负责人:CARL H. JUNE
-
依托单位:
Core E: Molecular Gene Delivery/Modification Core
-
批准号:8066106
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2010
-
负责人:CARL H. JUNE
-
依托单位:
海外基金